PwC: Women’s Healthcare Expected to Reach US$600bn by 2030

PwC has released its report From margin to mainstream - The future of women’s health.

According to the company’s 2026 report, “women’s health is one of the most undercapitalised growth markets in healthcare today.”

Despite women representing roughly half of the global population and driving the majority of healthcare decisions, they receive only about 5% of total healthcare R&D and investment funding. 

This gap reflects a long-standing structural imbalance in research, product design and care delivery. 

However, closing this gap presents not only a clinical imperative but also a major economic opportunity, with the sector projected to exceed US$600bn globally by 2030. 

Women’s health beyond reproductive care

The PwC report emphasises that women’s health has historically been treated as a niche category focused largely on reproductive care, but this definition is too limited. 

A broader perspective includes conditions unique to women, such as menopause and gynecological disorders, as well as diseases that affect women differently, including cardiovascular disease and mental health conditions. 

It also encompasses conditions that disproportionately affect women, such as autoimmune diseases, osteoporosis and Alzheimer’s disease. 

This expanded lens highlights how women bear a significant burden of high-cost and widely prevalent conditions across healthcare systems. 

Despite this, much of modern medicine has been developed using male biology as the default, contributing to gaps in diagnosis and treatment.

“This is work I care deeply about,” says Glenn Hunzinger, Health Industries Leader at PwC US on linkedIn.

“Despite representing roughly half the global population and driving the majority of healthcare decisions, women’s health has historically received only ~5% of healthcare R&D and investment funding. 

“That’s not just an equity issue, it’s a structural market inefficiency.” 

Addressing this imbalance is not only a matter of equity but also a way to correct inefficiencies in how healthcare markets have been historically defined and funded.

Health journeys and market opportunities

PwC reframes women’s health as a longitudinal, life-course issue, rather than a set of isolated medical events. 

Women’s health needs evolve from adolescence through early adulthood, midlife and advanced age, spanning areas such as: 

• Mental health
• Reproductive health
• Cardiovascular conditions
• Neurodegenerative diseases. 

This continuity creates sustained demand for healthcare services and highlights the importance of integrated, long-term care models. 

From menstrual health and fertility in younger years to menopause and chronic disease management later in life, women require consistent and coordinated care. 

This life-course approach also reinforces the idea that women’s health is not episodic but continuous, requiring healthcare systems to adapt accordingly. 

As a result, the sector represents not only a clinical priority but also a durable and expanding market opportunity across multiple stages of life. 

A US$600bn healthcare market

The report identifies women’s health as a rapidly growing economic sector, currently valued at approximately US$430bn to US$440bn globally across pharmaceuticals, diagnostics, providers and consumer health solutions. 

This is projected to grow to more than US$600bn by 2030, representing a 6–8% compound annual growth rate. 

Within this, core women’s health segments alone, such as fertility, pregnancy, gynecological care, oncology and menopause, are expected to increase from around US$195bn to US$205bn today to US$270bn to US$280bn by 2030. 

Growth is particularly strong in areas with high unmet need and innovation, including women’s oncology, menopause care and autoimmune diseases, where women make up 70–80% of patients in some conditions. 

Additionally, pharmaceutical innovation is projected to grow 8–10% annually, while consumer health technology, such as digital platforms and at-home diagnostics, is expected to expand even faster at 14–17% per year. 

These trends suggest that current forecasts may underestimate the full scale of future growth.

“Our analysis shows core women’s health and adjacent conditions already represent a ~US$430bn–US$440bn global market, projected to exceed US$600bn by 2030,” says Glenn on LinkedIn.

“And the definition is expanding beyond reproductive care, across the life course, and into cardiovascular, autoimmune, neurodegenerative, and behavioral health. 

“Private capital is responding. Innovation is accelerating. 

“Regulatory guidance is evolving. We are at an inflection point. 

“Women’s health is not a niche category. It is one of the most consequential growth opportunities in modern healthcare and the leaders who move early will help define what comes next.”

The shift to digital care

Investment in women’s health is accelerating, with nearly US$60bn in private capital deployed between 2020 and 2025 across venture capital, private equity and corporate funding. 

While early investment focused heavily on fertility and reproductive care, funding is now diversifying into areas such as menopause, oncology, cardiovascular disease and digital health solutions. 

Menopause care, for example, is one of the fastest-growing investment categories, expanding at approximately 13% annually. 

At the same time, innovation in diagnostics and medical devices is enabling earlier detection, less invasive treatments and more personalised care. 

A key trend highlighted by PwC is the shift from traditional, clinic-based care to technology-enabled, continuous care models, supported by AI, wearable devices and virtual platforms. 

These tools allow for more personalised, data-driven healthcare and are reshaping how women engage with the healthcare system. 

As digital adoption increases, women’s health is transitioning from episodic treatment to ongoing health management, marking a significant evolution in care delivery.